You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm said that ePlex revenues grew 98 percent compared to Q3 2018, and the firm placed 51 net new ePlex analyzers.
The firm is looking to expand its sales internationally, as well as in the consumer-initiated market, but is being conservative with revenue growth estimates.
The firm said that total revenue was lower than expected due to the timing of orders in its flow cytometry operations in the third quarter.
The Temple City, California-based NGS genetic testing firm more than doubled its number of billable tests compared to the prior-year period.
The company reported $33.8 million in total revenues for the quarter and said testing services revenues rose 68 percent year over year.
The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.
Clinical services revenues rose 56 percent to $92.6 million while pharma services grew 26 percent to $12.1 million.
Overall growth was driven by growth in sequencing instrument and consumables sales, which offset a 24 percent decline in microarray revenues.
The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.
Researchers have sequenced the genome of "the Methuselah of freshwater fish."
The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.
In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.